NANJING, SHANGHAI, CHINA, SAN JOSE & SAN FRANCISCO, CALIF., U.S., March 1, 2022 - IASO Biotherapeutics (“IASO Bio”), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products announced that the company’s commercial manufacturing facility in Nanjing successfully passed a comprehensive inspection by the Medical Products Administration of Province Jiangsu (JSMPA) and was granted a drug manufacturing license.
NANJING&SHANGHAI , CHINA, SAN JOSE U.S., February 14, 2022 - IASO Biotherapeutics (“IASO Bio”), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, and Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), today jointly announced that the Office of Orphan Products Development (OOPD) of the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to their fully human anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy (IASO Bio: CT103A, Innovent: IBI326) for the treatment of relapsed and/or refractory multiple myeloma (R/R MM).
Agreement combines IASO Bio and Innovent's CAR construct, validated in clinical trials, with Sana's in vivo and ex vivo engineered cell therapy programs
